Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat
- 1 May 2012
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 64 (5) , 637-643
Abstract
Objectives: To determine whether the glucagon-like 1 peptide analogue exendin-4 (EX-4) augments the neurochemical effects of a single L-DOPA treatment and whether EX-4 can decrease L-DOPA induced dyskinesias (LIDS). Methods: Rats were lesioned with 6-hydroxydopamine (6-OHDA) and 7 days later given EX-4 for 7 days. The following day, rats were given L-DOPA and extracellular dopamine was measured. The animals were then killed to determine tissue dopamine. To study LIDS, EX-4 and/or L-DOPA were co-administered daily, 7 days after 6-OHDA. LIDS were determined on Days 2, 4, 8, 12 and 16 prior to neurochemical assessment. Key findings: EX-4 reduced 6-OHDA induced damage. Acute effects of L-DOPA were potentiated by EX-4 in lesioned rats. Treatments with EX-4 caused a progressive reduction in LIDS. Conclusions: EX-4 treatment potentiates the effects of a single dose of L-DOPA. This augmentation indicates that lower L-DOPA doses might be used to the same effect in patients. The reduction in LIDS suggests that co-treatment with EX-4 could allow the use of L-DOPA with fewer side-effects and possibly therefore allow earlier introduction of L-DOPA in the clinic.Keywords
This publication has 23 references indexed in Scilit:
- Pre-treatment with dopamine agonists influence l-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned ratBehavioural Brain Research, 2010
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismProceedings of the National Academy of Sciences, 2009
- Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's diseaseJournal of Neuroinflammation, 2008
- Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's diseaseJournal of Neuroscience Research, 2007
- The corticotrophin‐releasing factor‐like peptide urocortin reverses key deficits in two rodent models of Parkinson's diseaseEuropean Journal of Neuroscience, 2007
- Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implicationsThe Lancet Neurology, 2006
- Dopaminergic Neurons Protected from Degeneration by GDNF Gene TherapyScience, 1997
- Regional Effects of Sodium Valproate on Extracellular Concentrations of 5‐Hydroxytryptamine, Dopamine, and Their Metabolites in the Rat Brain: An In Vivo Microdialysis StudyJournal of Neurochemistry, 1992
- Levodopa‐induced dyskinesiaNeurology, 1990
- SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 1977